Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

被引：1

作者：

Croop, Robert ^{[1
]}

Ailani, Jessica ^{[2
]}

Kudrow, David

Smith, Timothy ^{[3
]}

Lipton, Richard ^{[4
]}

Thiry, Alexandra ^{[1
]}

Jensen, Christopher ^{[1
]}

Kamen, Lisa ^{[1
]}

机构：

[1] Biohaven Pharmaceut, New Haven, CT USA

[2] Medstar Georgetown Neurol, Washington, DC USA

[3] Study Metrix Res, St Petersburg, FL USA

[4] Albert Einstein Coll Med, New York, NY USA

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000202051

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P10-12.010

引用

页数：6

共 50 条

[11] Safety and tolerability of rimegepant every other day for preventive treatment of migraine plus as-needed for acute treatment of migraine: Results from a 52-week, open-label extension study
Lipton, R. B.
Kudrow, D.
Smith, T. R.
Ailani, J.
Kamen, L.
Thiry, A. C.
Jensen, C. M.
Coric, V
Croop, R.
HEADACHE, 2022, 62 : 99 - 99
[12] Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
Lipton, R.
Kudrow, D.
Smith, T.
Ailani, J.
Kamen, L.
Thiry, A. C.
Jensen, C. M.
Coric, V.
Croop, R.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[13] Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Phase
Lipton, Richard
Kudrow, David
Smith, Timothy
Ailani, Jessica
Goadsby, Peter
Kamen, Lisa
Thiry, Alexandra
Jensen, Christopher
Croop, Robert
NEUROLOGY, 2023, 100 (17)
[14] Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: A 52-week open-label study
Peters-Strickland T.
Baker R.A.
McQuade R.D.
Jin N.
Eramo A.
Perry P.
Johnson B.R.
Duca A.
Sanchez R.
npj Schizophrenia, 1 (1):
[15] Rimegepant 75 mg is Associated With Significant Reductions in Monthly Migraine Days: Post-Hoc Analyses of a Multicenter, Open Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine
McGinley, J. S.
L'Italien, G. J.
Thiry, A. C.
Croop, R.
Coric, V
Lipton, R. B.
HEADACHE, 2020, 60 : 118 - 120
[16] Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study
Smith, T. R.
Glazer, R. D.
Koren, M. J.
Wernsing, M.
Zhang, Y.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) : 1367 - 1374
[17] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Tepper, Stewart J.
Ashina, Messoud
Reuter, Uwe
Brandes, Jan Lewis
Dolezil, David
Silberstein, Stephen D.
Winner, Paul
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
CEPHALALGIA, 2020, 40 (06) : 543 - 553
[18] Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial
Ashina, M.
Tepper, S. J.
Reuter, U.
Blumenfeld, A. M.
Hutchinson, S.
Xia, J.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 163 - 163
[19] Atogepant 60 mg once-daily shows efficacy for the preventive treatment of migraine: Results from a 52-week open-label extension trial
Ashina, M.
Tepper, S. J.
Reuter, U.
Blumenfeld, A. M.
Hutchinson, S.
Xia, J.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
HEADACHE, 2021, 61 : 91 - 92
[20] Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial
Ashina, M.
Tepper, S. J.
Reuter, U.
Blumenfeld, A. M.
Hutchinson, S.
Xia, J.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 110 - 110

← 1 2 3 4 5 →